Rapid communication: A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis

Tobias Larsson, Xijie Yu, Siobhan I. Davis, Mohamad S. Draman, Sean D. Mooney, Michael J. Cullen, Kenneth White

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Gain-of-function mutations in fibroblast growth factor-23 (FGF23) are responsible for autosomal dominant hypophosphatemic rickets, a disorder of isolated renal phosphate wasting. Patients with the disorder display hypophosphatemia with normocalcemia as well as inappropriately normal 1,25-dihydroxyvitainin D [1,25(OH)2D3] concentrations. Reciprocally tumoral calcinosis (TC) patients are often hyperphosphatemic with inappropriately normal or elevated serum 1,25(OH)2D3 levels and have eciopic and vascular calcifications, a phenotype similar to that of Fgf23 null mice. Therefore, the goal of the present studies was to test whether FGF23 was a candidate gene for TC. Two sisters in a consanguineous TC family had hyperphosphatemia and normal 1,25(OH)2D3 levels with characteristic ectopic and vascular calcifications. Interestingly, these patients had low-normal intact serum FGF23 levels but demonstrated FGF23 concentrations approximately 40 times normal when assessed with a C-terminal FGF23 serum assay. Mutational analyses identified a homozygous S71G mutation in FGF23 in the TC patients, which was not found in control alleles. Finally, modeling demonstrated that the S71G mutation most likely destabilizes full-length FGF23. In summary, recessive FGF23 mutations can lead to TC. Additionally, our findings indicate that FGF23 may adopt an unstable conformation in some TC patients, possibly leading to nonfunctional FGF23 protein.

Original languageEnglish
Pages (from-to)2424-2427
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume90
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Calcinosis
Communication
Mutation
Vascular Calcification
Serum
fibroblast growth factor 23
Hyperphosphatemia
Hypophosphatemia
Conformations
Siblings
Assays
Genes
Alleles
Phosphates
Display devices
Phenotype
Kidney

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Rapid communication : A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. / Larsson, Tobias; Yu, Xijie; Davis, Siobhan I.; Draman, Mohamad S.; Mooney, Sean D.; Cullen, Michael J.; White, Kenneth.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 90, No. 4, 04.2005, p. 2424-2427.

Research output: Contribution to journalArticle

Larsson, Tobias ; Yu, Xijie ; Davis, Siobhan I. ; Draman, Mohamad S. ; Mooney, Sean D. ; Cullen, Michael J. ; White, Kenneth. / Rapid communication : A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. In: Journal of Clinical Endocrinology and Metabolism. 2005 ; Vol. 90, No. 4. pp. 2424-2427.
@article{bc4005732b7b410985984b1e2dd0e64c,
title = "Rapid communication: A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis",
abstract = "Gain-of-function mutations in fibroblast growth factor-23 (FGF23) are responsible for autosomal dominant hypophosphatemic rickets, a disorder of isolated renal phosphate wasting. Patients with the disorder display hypophosphatemia with normocalcemia as well as inappropriately normal 1,25-dihydroxyvitainin D [1,25(OH)2D3] concentrations. Reciprocally tumoral calcinosis (TC) patients are often hyperphosphatemic with inappropriately normal or elevated serum 1,25(OH)2D3 levels and have eciopic and vascular calcifications, a phenotype similar to that of Fgf23 null mice. Therefore, the goal of the present studies was to test whether FGF23 was a candidate gene for TC. Two sisters in a consanguineous TC family had hyperphosphatemia and normal 1,25(OH)2D3 levels with characteristic ectopic and vascular calcifications. Interestingly, these patients had low-normal intact serum FGF23 levels but demonstrated FGF23 concentrations approximately 40 times normal when assessed with a C-terminal FGF23 serum assay. Mutational analyses identified a homozygous S71G mutation in FGF23 in the TC patients, which was not found in control alleles. Finally, modeling demonstrated that the S71G mutation most likely destabilizes full-length FGF23. In summary, recessive FGF23 mutations can lead to TC. Additionally, our findings indicate that FGF23 may adopt an unstable conformation in some TC patients, possibly leading to nonfunctional FGF23 protein.",
author = "Tobias Larsson and Xijie Yu and Davis, {Siobhan I.} and Draman, {Mohamad S.} and Mooney, {Sean D.} and Cullen, {Michael J.} and Kenneth White",
year = "2005",
month = "4",
doi = "10.1210/jc.2004-2238",
language = "English",
volume = "90",
pages = "2424--2427",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Rapid communication

T2 - A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis

AU - Larsson, Tobias

AU - Yu, Xijie

AU - Davis, Siobhan I.

AU - Draman, Mohamad S.

AU - Mooney, Sean D.

AU - Cullen, Michael J.

AU - White, Kenneth

PY - 2005/4

Y1 - 2005/4

N2 - Gain-of-function mutations in fibroblast growth factor-23 (FGF23) are responsible for autosomal dominant hypophosphatemic rickets, a disorder of isolated renal phosphate wasting. Patients with the disorder display hypophosphatemia with normocalcemia as well as inappropriately normal 1,25-dihydroxyvitainin D [1,25(OH)2D3] concentrations. Reciprocally tumoral calcinosis (TC) patients are often hyperphosphatemic with inappropriately normal or elevated serum 1,25(OH)2D3 levels and have eciopic and vascular calcifications, a phenotype similar to that of Fgf23 null mice. Therefore, the goal of the present studies was to test whether FGF23 was a candidate gene for TC. Two sisters in a consanguineous TC family had hyperphosphatemia and normal 1,25(OH)2D3 levels with characteristic ectopic and vascular calcifications. Interestingly, these patients had low-normal intact serum FGF23 levels but demonstrated FGF23 concentrations approximately 40 times normal when assessed with a C-terminal FGF23 serum assay. Mutational analyses identified a homozygous S71G mutation in FGF23 in the TC patients, which was not found in control alleles. Finally, modeling demonstrated that the S71G mutation most likely destabilizes full-length FGF23. In summary, recessive FGF23 mutations can lead to TC. Additionally, our findings indicate that FGF23 may adopt an unstable conformation in some TC patients, possibly leading to nonfunctional FGF23 protein.

AB - Gain-of-function mutations in fibroblast growth factor-23 (FGF23) are responsible for autosomal dominant hypophosphatemic rickets, a disorder of isolated renal phosphate wasting. Patients with the disorder display hypophosphatemia with normocalcemia as well as inappropriately normal 1,25-dihydroxyvitainin D [1,25(OH)2D3] concentrations. Reciprocally tumoral calcinosis (TC) patients are often hyperphosphatemic with inappropriately normal or elevated serum 1,25(OH)2D3 levels and have eciopic and vascular calcifications, a phenotype similar to that of Fgf23 null mice. Therefore, the goal of the present studies was to test whether FGF23 was a candidate gene for TC. Two sisters in a consanguineous TC family had hyperphosphatemia and normal 1,25(OH)2D3 levels with characteristic ectopic and vascular calcifications. Interestingly, these patients had low-normal intact serum FGF23 levels but demonstrated FGF23 concentrations approximately 40 times normal when assessed with a C-terminal FGF23 serum assay. Mutational analyses identified a homozygous S71G mutation in FGF23 in the TC patients, which was not found in control alleles. Finally, modeling demonstrated that the S71G mutation most likely destabilizes full-length FGF23. In summary, recessive FGF23 mutations can lead to TC. Additionally, our findings indicate that FGF23 may adopt an unstable conformation in some TC patients, possibly leading to nonfunctional FGF23 protein.

UR - http://www.scopus.com/inward/record.url?scp=17844402245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844402245&partnerID=8YFLogxK

U2 - 10.1210/jc.2004-2238

DO - 10.1210/jc.2004-2238

M3 - Article

C2 - 15687325

AN - SCOPUS:17844402245

VL - 90

SP - 2424

EP - 2427

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -